Dongcheng Biochemicals' diagnostic agent gains insurance, new drug enters trials

Yantai Dongcheng Biochemicals announced its technetium [99mTc] tetrofosmin injection, a diagnostic agent for coronary artery disease, has been included in China’s 2025 National Medical Insurance Drug Catalog, effective January 1, 2026. This inclusion is expected to enhance patient access to SPECT-MPI examinations and promote the product's market penetration. The drug is categorized under "Cardiovascular diagnostic radiopharmaceuticals" and will be listed as type "B."

Additionally, the company’s subsidiary, Yantai Lanna Biotech Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of 177Lu-LNC1009 injection. This novel dual-target radiopharmaceutical targets fibroblast activation protein (FAP) and integrin αvβ3, aiming to treat advanced solid tumors. As of the announcement date, the accumulated R&D investment for this project reached CNY 1,357.90.

The company cautioned that the successful development and commercialization of 177Lu-LNC1009 injection are subject to the inherent risks of clinical trials, regulatory approvals, and market uncertainties. Both developments underscore the company's commitment to advancing medical diagnostics and treatments.